Patent intelligence · AU
AU 2019273664
Methods for the treatment of psoriatic arthritis
Methods for the treatment of psoriatic arthritis
Patent details — AU 2019273664
- Jurisdiction
- AU
- Status
- granted
- Grant date
- Jan 21, 2021
- Expiration
- Jan 16, 2041
- Applicant
- ALFASIGMA SPA [IT]
- CPC classes
- A61K 31/ 541 A I, A61K/31541, A61P 17/ 06 A I, A61P 19/ 02 A I
Quick answer
AU 2019273664 (Methods for the treatment of psoriatic arthritis) is held by ALFASIGMA SPA [IT]. Status: granted. Granted Jan 21, 2021. Expires Jan 16, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALFASIGMA SPA [IT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 541 A I, A61K/31541, A61P 17/ 06 A I, A61P 19/ 02 A I, A61P/1706, A61P/1902
More from ALFASIGMA SPA [IT]
Related pharmaceutical patents in our USPTO index.
-
WO 2026027669
BIOMARQUEURS POUR DÉTERMINER LE TRAITEMENT DE LA RECTOCOLITE HÉMORRAGIQUE AVEC DU FILGOTINIB
granted -
IT 202300014295
COMPOSIZIONI ORODISPERSIBILI COMPRENDENTI BETAMETASONE FOSFATO
granted -
IT 202300012522
FLUOROMETIL-CARNITINA PER USO COME INIBITORE DI COLINA TRIMETILAMMINA (TMA) LIASI.
granted -
AU 2023257308
USES OF FARNESOID X RECEPTOR AGONISTS
granted -
IT 202300006237
COMPOSIZIONI NUTRACEUTICHE PER IL TRATTAMENTO O PREVENZIONE DI DISORDINI CONNESSI ALLA TRIMETILAMINURIA.
granted -
IT 202300001434
PRODOTTO DI FERMENTAZIONE PER USO NEL TRATTAMENTO DI PATOLOGIE ASSOCIATE ALLA SINDROME METABOLICA E STEATOSI EPATICA.
granted -
CA 3263063
VELUSETRAG DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE LA PSEUDO-OBSTRUCTION INTESTINALE CHRONIQUE (POIC)
granted -
IT 202200013882
PRODOTTO DI FERMENTAZIONE PER IL TRATTAMENTO DI MALATTIE INFIAMMATORIE.
granted
Frequently asked questions
What is US patent 2019273664?
AU 2019273664 (Methods for the treatment of psoriatic arthritis) is held by ALFASIGMA SPA [IT]. Status: granted. Granted Jan 21, 2021. Expires Jan 16, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns AU 2019273664?
ALFASIGMA SPA [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does AU 2019273664 expire?
Our index shows an expiration date of Jan 16, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.